Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Aranda-Michel, J.
space
  arrow  Weber, F. L., Jr.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Nefazodone-Induced Liver Failure: Report of Three Cases

right arrow Jaime Aranda-Michel, MD; Alison Koehler, MD; Pablo A. Bejarano, MD; John E. Poulos, MD; Bruce A. Luxon, MD; Chaudhary Mobin Khan, MD; Looi C. Ee, MD; William F. Balistreri, MD; and Fredrick L. Weber, Jr., MD

16 February 1999 | Volume 130 Issue 4 Part 1 | Pages 285-288

Background: Liver failure is a rare but devastating result of drug toxicity.

Objective: To describe three cases of subfulminant liver failure that were probably caused by nefazodone, a new antidepressant that is a synthetically derived phenylpiperazine.

Design: Case series.

Setting: Two university medical centers and a children's hospital.

Patients: Three women 16 to 57 years of age.

Intervention: Two patients underwent liver transplantation; the third was listed for transplantation but subsequently improved.

Measurement: Liver biopsy.

Results: Nefazodone was administered for 14 to 28 weeks before the onset of symptoms. The duration of jaundice before onset of encephalopathy ranged from 4 to 6 weeks. All cases of liver failure had similar histologic appearance, with prominent necrosis in the centrolobular areas (zone 3). One patient had successful liver transplantation, one underwent transplantation but died, and one improved without transplantation. The temporal onset of disease after the start of nefazodone therapy suggested severe hepatocellular injury caused by the drug.

Conclusions: Because nefazodone seems to cause severe hepatocellular injury in an idiosyncratic manner, routine liver chemistries should be performed before starting nefazodone therapy and patients should be monitored regularly. Therapy should be discontinued if liver enzyme concentrations become abnormal.

Author and Article Information
space

From University of Cincinnati and Children's Hospital Medical Center, Cincinnati, Ohio; and St. Louis University, St. Louis, Missouri.

Acknowledgments: The authors thank David Movick, MD, and Andrew Minkin, MD, for referring these patients.

Requests for Reprints: Fredrick L Weber Jr., MD, Liver Unit, Division of Digestive Diseases, University of Cincinnati Medical Center, 231 Bethesda Avenue, ML 595, Cincinnati, OH 45267.

Current Author Addresses: Drs. Aranda-Michel and Weber: Liver Unit, Division of Digestive Diseases, University of Cincinnati Medical Center, 231 Bethesda Avenue, ML 595, Cincinnati, OH 45267.

Drs. Koehler and Bejarano: Department of Pathology, University of Cincinnati Medical Center, 231 Bethesda Avenue, Cincinnati, OH 45267.

Drs. Poulos, Luxon, and Mobin Khan: Division of Gastroenterology and Hepatology, St. Louis University, 3635 Vista Avenue at Grand Boulevard, St. Louis, MO 63110.

Drs. Ee and Balistreri: Division of Pediatric Gastroenterology and Nutrition, Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229.




This article has been cited by other articles:


Home page
Toxicol SciHome page
J. A. Dykens, J. D. Jamieson, L. D. Marroquin, S. Nadanaciva, J. J. Xu, M. C. Dunn, A. R. Smith, and Y. Will
In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone
Toxicol. Sci., June 1, 2008; 103(2): 335 - 345.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. P DeSanty and C. M Amabile
Antidepressant-Induced Liver Injury
Ann. Pharmacother., July 1, 2007; 41(7): 1201 - 1211.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
C. C. Crone, G. M. Gabriel, and A. DiMartini
An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist
Psychosomatics, June 1, 2006; 47(3): 188 - 205.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
S. E. Kostrubsky, S. C. Strom, A. S. Kalgutkar, S. Kulkarni, J. Atherton, R. Mireles, B. Feng, R. Kubik, J. Hanson, E. Urda, et al.
Inhibition of Hepatobiliary Transport as a Predictive Method for Clinical Hepatotoxicity of Nefazodone
Toxicol. Sci., April 1, 2006; 90(2): 451 - 459.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. S. Kalgutkar, A. D. N. Vaz, M. E. Lame, K. R. Henne, J. Soglia, S. X. Zhao, Y. A. Abramov, F. Lombardo, C. Collin, Z. S. Hendsch, et al.
BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4
Drug Metab. Dispos., February 1, 2005; 33(2): 243 - 253.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
L. J. Fochtmann and A. J. Gelenberg
Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
Focus, January 1, 2005; 3(1): 34 - 42.
[Full Text] [PDF]


Home page
NEJMHome page
W. M. Lee
Drug-Induced Hepatotoxicity
N. Engl. J. Med., July 31, 2003; 349(5): 474 - 485.
[Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1999 by the American College of Physicians.